AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
28 Jul 2017 11:00 AM
RNS
Director/PDMR Shareholding
27 Jul 2017 07:15 AM
RNS
Tagrisso significantly improves FLAURA
27 Jul 2017 07:11 AM
RNS
AZ reports initial results from MYSTIC lung trial
27 Jul 2017 07:06 AM
RNS
AZ & MERCK ESTABLISH STRATEGIC ONCOLOGY DEAL
27 Jul 2017 07:00 AM
RNS
AstraZeneca PLC - H1 2017 Results
26 Jul 2017 04:46 PM
RNS
Faslodex receives EU approval for 1L breast cancer
21 Jul 2017 03:45 PM
RNS
Holding(s) in Company
03 Jul 2017 02:59 PM
RNS
Total Voting Rights
03 Jul 2017 07:00 AM
RNS
AZ COMPLETES SELOKEN AGREEMENT WITH RECORDATI
03 Jul 2017 07:00 AM
RNS
AZ COMPLETES ZOMIG DIVESTMENT WITH GRÜNENTHAL
23 Jun 2017 12:46 PM
RNS
Faslodex CHMP positive opinion in 1L breast cancer
07 Jun 2017 07:13 AM
RNS
AZ agreement with Grünenthal for rights to Zomig
06 Jun 2017 07:00 AM
RNS
ASTRAZENECA PRICES A $2BN BOND ISSUE
05 Jun 2017 07:00 AM
RNS
LYNPARZA: SIGNIFICANT PFS IN BRCAm BREAST CANCER
01 Jun 2017 03:00 PM
RNS
Block listing Interim Review
01 Jun 2017 03:00 PM
RNS
Total Voting Rights
31 May 2017 07:00 AM
RNS
Directorate Change
24 May 2017 03:00 PM
RNS
Director/PDMR Shareholding
23 May 2017 07:00 AM
RNS
Bydureon EXSCEL trial meets T2D safety objective
22 May 2017 07:00 AM
RNS
AZ AGREEMENT WITH RECORDATI FOR SELOKEN IN EUROPE
16 May 2017 03:00 PM
RNS
Director/PDMR Shareholding
12 May 2017 07:00 AM
RNS
IMFINZI SIGNIFICANT PFS - UNRESECTABLE LUNG CANCER
10 May 2017 07:00 AM
RNS
AZ updates on tralokinumab trial in severe asthma
02 May 2017 02:00 PM
RNS
Total Voting Rights
02 May 2017 07:00 AM
RNS
DURVALUMAB RECEIVES US FDA ACCELERATED APPROVAL
27 Apr 2017 05:30 PM
RNS
Result of AGM
27 Apr 2017 07:00 AM
RNS
AstraZeneca: Q1 2017 Results
25 Apr 2017 01:30 PM
RNS
TAGRISSO RECEIVES FULL APPROVAL IN THE EU
03 Apr 2017 03:00 PM
RNS
Total Voting Rights
31 Mar 2017 07:01 AM
RNS
Tagrisso (osimertinib) receives FDA full approval
31 Mar 2017 07:00 AM
RNS
AZ COMPLETES AGREEMENT WITH TERSERA THERAPEUTICS
28 Mar 2017 04:00 PM
RNS
Director/PDMR Shareholding
27 Mar 2017 03:00 PM
RNS
Director/PDMR Shareholding
17 Mar 2017 07:00 AM
RNS
US FDA issues CRL for ZS-9 in hyperkalaemia
16 Mar 2017 11:00 AM
RNS
Notice of AGM
15 Mar 2017 07:00 AM
RNS
LYNPARZA PFS IN BRCA OVARIAN MAINTENANCE THERAPY
08 Mar 2017 07:00 AM
RNS
Filing of Form 20-F with SEC
07 Mar 2017 02:30 PM
RNS
Annual Financial Report
06 Mar 2017 07:00 AM
RNS
Directorate Change
03 Mar 2017 07:00 AM
RNS
ALLIANCE WITH SANOFI PASTEUR FOR MEDI8897
01 Mar 2017 04:30 PM
RNS
Total Voting Rights
28 Feb 2017 07:02 AM
RNS
FDA approves once-daily Qtern for type-2 diabetes
24 Feb 2017 12:32 PM
RNS
CHMP positive opinion for ZS-9 in hyperkalaemia
20 Feb 2017 07:00 AM
RNS
AZ licenses Zoladex to TerSera for the US & Canada
17 Feb 2017 07:00 AM
RNS
Lynparza positive in metastatic BRCA breast cancer
16 Feb 2017 12:01 PM
RNS
SILIQ (BRODALUMAB) APPROVED BY US FDA
02 Feb 2017 07:00 AM
RNS
AZN: FY16 and Q4 2016 Results
01 Feb 2017 04:00 PM
RNS
Total Voting Rights
26 Jan 2017 10:00 AM
RNS
SYMBICORT GRANTED PAEDIATRIC EXCLUSIVITY IN THE US
17 Jan 2017 07:00 AM
RNS
AZ 1st-line lung cancer immuno-oncology programme
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100

Latest directors dealings